For Healthcare Professionals Outside the US
Tafinlar + Mekinist is indicated for adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Efficacy > BRAF V600+ NSCLC > Disease Control Rate

An effective, targeted combination that provides demonstrated results

Treatment-naïve patients with BRAF V600+ NSCLC: Maximum reduction in target lesions (investigator assessed)1

TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) efficacy in treatment-naïve patient

Previously treated patients with BRAF V600+ NSCLC: Maximum reduction in target lesions (investigator-assessed)1

TAFINLAR® (dabrafenib) and MEKINIST® (trametinib) efficacy in previously treated patients
CR, complete response; DCR, disease control rate; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.
Reference: 1. Data on file (Planchard manuscript); Novartis Pharmaceuticals Corp; 2020. 

COVID-19 Update

Novartis is closely monitoring the evolving COVID-19 pandemic. For the most recent information on how Novartis is responding, visit the COVID-19 Information Center.

During this time of uncertainty it is important to communicate with your patients about COVID-19 to clarify that they should not stop their treatments except under the direction of the treating physician, and to ensure that patients have sufficient drug to avoid any treatment interruptions.

Reach out to your Novartis representative with any questions related to Novartis products.

04/20  G-ONC-1230566

COMBI-AD was a double-blind, placebo-controlled, Phase 3 trial that compared Tafinlar + Mekinist vs placebo4


  • Resection of histologically confirmed Stage IIIA, B, or C with BRAF V600E or BRAF V600K mutation
  • ECOG performance status ≤1
  • No prior systemic anticancer treatment or radiotherapy for melanoma
2 mg QD (n=438)

Placebo (n=432)


  • Primary endpoint was RFS
  • Secondary endpoints were OS, distant metastasis-free survival, freedom from relapse, and safety
COMBI-d phase 3 study: Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs Tafinlar® monotherapy